Key result
Olaratumab links to ~8 months median progression-free survival in advanced soft tissue sarcoma.
Why the study?
Olaratumab was withdrawn from the market due to disappointing phase III study results, prompting evaluation of its effect on soft tissue sarcomas in clinical practice.
What are the progression-free and overall survival outcomes of Olaratumab in adult patients with advanced/metastatic soft tissue sarcomas?
Observational (n=15)
No
What are the progression-free and overall survival outcomes of Olaratumab in adult patients with advanced/metastatic soft tissue sarcomas?
In a small retrospective cohort, Olaratumab showed a median PFS of 7.87 months and median OS of 9.8 months in advanced soft tissue sarcoma, consistent with literature prior to its market withdrawal.
Answers are grounded in this paper and cite their sources.
Cohort experience with olaratumab in sarcomas is hypothesis-generating; leaves open its role in rare subtypes after phase III withdrawal.
Soft tissue sarcomas remain one of the rarest malignancies with numerous subtypes that go undiagnosed. The PDGFRα antagonist Olaratumab (Lartruvo) was withdrawn from the market due to disappointing findings in the phase III studies. We share our experience with this medication in a tertiary care center in the Middle East and North Africa region. Monitor the effect of Olaratumab on sarcomas when it was used prior to its withdrawal, and compare our findings with the literature. We performed a retrospective analysis of adult patients with advanced-/metastatic soft tissue sarcomas treated with at least two cycles of Olaratumab at a tertiary care center in Lebanon during the period from January 1, 2017 to December 31, 2018. Fifteen patients were included in the study. The mean age was 49 with a range of 26-75 years. The median duration of the use of Olaratumab was 21.3 months with a range of 7.3-37 months. The average number of number of cycles received per patient was four. Five patients were deceased. Median PFS was 7.87 months (95% CI 5.28-10.45), and mean OS was 12.26 months (95% CI 8.47-16.05) Median OS was 9.8 months (95% CI 6.07-13.53). Olaratumab has been withdrawn from the market, and it is currently being investigated as part of the phase II ANNOUNCE 2 trial. Our experience from a tertiary care center shows results similar to those reported in the literature. The immunogenicity and heterogeneity of soft tissue sarcomas pose a challenge to the treatment of soft tissue sarcomas, but they also allow a wide array of possible management solutions.
No takes yet. Share an insight, caveat, or question.
Zerdan et al. (2021) conducted an observational in Advanced/metastatic soft tissue sarcomas (n=15). Olaratumab was evaluated on Progression-free survival (PFS) in months (95% CI 5.28-10.45). In patients with advanced or metastatic soft tissue sarcomas, Olaratumab treatment resulted in a median progression-free survival of 7.87 months and a median overall survival of 9.8 months.
Synapse has enriched 10 related papers. Consider them for comparative context: